Defunct Company
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
3,335
NCT01856439
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
Phase: Phase 1/2
Role: Lead Sponsor
Start: May 31, 2011
Completion: Apr 30, 2022
NCT02585934
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
Phase: Phase 3
Start: Oct 31, 2015
Completion: Sep 30, 2017
NCT02640729
Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia
Phase: Phase 2
Start: Dec 31, 2015
Completion: Nov 30, 2017
NCT02669433
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
Start: Jan 31, 2016
Completion: Dec 31, 2017
NCT02708186
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Start: Mar 31, 2016
Completion: May 31, 2018
NCT02586909
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
Start: Apr 26, 2016
Completion: Mar 12, 2018
NCT02871427
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
Start: Oct 20, 2016
Completion: Jan 17, 2019
NCT02910102
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
Start: Oct 31, 2016
NCT02928445
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
Phase: Phase 2/3
Completion: Feb 28, 2018